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ackground & Aims: Growth hormone (GH) is used to
reat growth delay in children with Crohn’s disease and
n patients with short-bowel syndrome. GH can increase
ollagen accumulation in intestinal mesenchymal cells,
aising concern that GH therapy could exacerbate fibro-
is in patients with Crohn’s disease. We tested if GH
reatment altered inflammation or fibrosis during
hronic, experimental granulomatous enterocolitis.
ethods: Ileum and cecum of Lewis rats were subsero-
ally injected with peptidoglycan-polysaccharide (PG-
PS) or control human serum albumin. At the onset of
hronic PG-APS–induced inflammation, rats were ad-
inistered recombinant human GH or vehicle for 14
ays. Fibrosis and inflammation were quantified by
ross gut disease scoring, histologic scoring, type I col-
agen, and cytokine expression in cecum. Abundance
nd localization of suppressor of cytokine signaling-3
SOCS-3) messenger RNA and/or protein were deter-
ined in cecum. Effect of GH, cytokines, or PG-APS on
OCS-3 synthesis was measured in intestinal myofibro-
lasts. Myofibroblasts overexpressing SOCS-3 were used
o test whether SOCS-3 inhibits collagen accumulation.
esults: In PG-APS–injected rats, GH modestly reduced
ross adhesions and mesenteric contractions, cecal fi-
rosis score, and collagen expression, but had no effect
n intestinal inflammation. GH increased SOCS-3 mes-
enger RNA and protein abundance in PG-APS rats and
OCS-3 messenger RNA was localized to the periphery
f granulomas. GH in combination with cytokines or
G-APS, but not alone, induced SOCS-3 synthesis in
ntestinal myofibroblasts. Myofibroblasts overexpressing
OCS-3 showed reduced cytokine-induced collagen ac-
umulation. Conclusions: GH modestly reduces intesti-
al fibrosis associated with chronic experimental entero-
olitis and stimulates expression of antifibrogenic
OCS-3, suggesting that GH therapy in inflammatory
owel disease should not exacerbate fibrosis.
ntestinal fibrosis is a common complication of Crohn’s
disease (CD) and generally is considered an excessive,
rreversible, wound-healing response to chronic transmu-
al inflammation.1 Fibrosis in this disorder involves over-rowth of the muscularis mucosa and muscularis pro-
ria,2 excessive collagen deposition,2,3 and mesenchymal
ell hyperplasia.4–6 Although fibrosis is variable in pre-
entation in CD, it can lead to stricture and partial or
omplete bowel obstruction, which are serious compli-
ations for which endoscopic balloon dilation or surgical
esection are the only current therapies.7,8 Unfortunately,
igh recurrence of inflammation and fibrosis in CD pa-
ients contributes to repeat surgeries and complications
nd can result in short-bowel syndrome (SBS), a malab-
orption syndrome resulting from insufficient functional
owel.7,8
Recombinant human growth hormone (rhGH), alone
r in combination with glutamine and modified diet, has
een tested as therapy in SBS patients in a number of
linical trials and was reported to improve weight gain
nd lean body mass and reduce the need for parenteral
utrition.9–13 Clinical trials of rhGH in SBS patients
eported varied outcomes on nutrient absorption and
rovided no consistent evidence about direct effects of
H on intestinal function or growth.9,11,14–16 The use of
hGH in SBS patients remains controversial, despite
ecent Food and Drug Administration approval.17 Some
BS patients treated with rhGH had CD, but no infor-
ation was reported regarding rhGH effects on inflam-
ation or fibrosis.9,10 rhGH therapy improved linear
rowth in pediatric CD patients with growth delay.18,19
clinical trial of a small number of patients with active
D reported that GH therapy in concert with a high-
rotein diet improved disease symptoms measured by the
rohn’s Disease Activity Index and decreased the need
Abbreviations used in this paper: GAPDH, glyceraldehyde-3-phos-
hate dehydrogenase; HSA, human serum albumin; IGF-I, insulin-like
rowth factor; IL, interleukin; PG-APS, peptidoglycan-polysaccharide;
hGH, recombinant human growth hormone; SBS, short bowel syn-
rome; SOCS-3, suppressor of cytokine signaling-3; TNF, tumor ne-
rosis factor .

































































































July 2005 GH REDUCES INTESTINAL FIBROSIS 205or other medications.20 Thus, there is clinical evidence
or benefits of GH in the setting of SBS and CD. How-
ver, potential effects of GH on fibrosis, a serious com-
lication of CD, have not been analyzed in the clinical
tudies or in animal models of inflammatory bowel dis-
ase (IBD).
Beneficial effects of GH on intestinal inflammation
ave been documented in animal models of colitis. Ad-
inistration of rhGH reduced inflammation in the tri-
itrobenzene sulfonic acid rat model of IBD.21,22 Trans-
enic mice overexpressing GH exhibited improved
ucosal repair after acute colitis induced by dextran
odium sulfate compared with wild-type mice.23 Im-
roved repair in transgenic mice overexpressing GH was
ssociated with more rapid but transient increases in
rypt cell proliferation. However, GH action on intesti-
al fibrosis was not analyzed in any of these studies.
verall, fibrosis during chronic inflammation has been
ess well studied than inflammation. This reflects the fact
hat many animal models of IBD do not exhibit fibrosis
nd analyses in clinical trials generally are limited to the
ucosa and not the submucosal layers, which are pre-
ominant sites of fibrosis. Concerns that GH treatment
ould exacerbate fibrosis stem from preliminary observa-
ions that GH stimulates collagen accumulation in cul-
ured intestinal myofibroblasts,24 the primary mesenchy-
al cell type thought to mediate intestinal fibrosis.6 GH
lso induces insulin-like growth factor-I (IGF-I) expres-
ion in some tissues and considerable evidence suggests
hat IGF-I may play a role in mediating fibrosis in CD.1
his raises the possibility that GH therapy in IBD
atients may increase directly or indirectly intestinal
ollagen deposition or fibrosis. This study tested the
ypothesis that therapeutically administered GH exacer-
ates fibrosis in a rat model of chronic intestinal inflam-
ation induced by peptidoglycan-polysaccharide poly-
ers derived from group A streptococci (PG-APS), one
f the few animal models characterized by fibrosis asso-
iated with chronic intestinal inflammation.25 When in-
ected subserosally into ileum and cecum of susceptible
at strains, PG-APS polymers induce acute inflammation
or 24–48 hours followed by remission of inflammation
nd then spontaneous reactivation between 10–20 days
fter injection with progression to chronic granuloma-
ous inflammation.26,27 This model particularly is rele-
ant to CD for a number of reasons. Reactivation and
hronic inflammation is T-cell mediated and accompa-
ied by systemic responses including arthritis, which is
lso a complication in a significant number of CD pa-
ients.28 Importantly, chronic inflammation induced by
G-APS is known to involve severe transmural fibrosis
nd smooth muscle hyperplasia,25 making this model warticularly useful for studying the possible effects of
herapeutic interventions on fibrosis. In the present
tudy, we tested whether GH given therapeutically after
eactivation of chronic inflammation altered the severity
f fibrosis associated with chronic PG-APS–induced en-
erocolitis. As well as testing the effects of GH on
brosis, we examined whether GH altered the severity of
ntestinal inflammation, key cytokine mediators of in-
ammation, or local expression of IGF-I, which is up-
egulated at sites of fibrosis in the PG-APS model29 and
n involved intestine of patients with CD.6,30,31 Our
tudy provides evidence that GH improves rather than
xacerbates intestinal fibrosis in the PG-APS model and
hat this is correlated with local induction of suppressor
f cytokine signaling-3 (SOCS-3). SOCS-3 is a cytokine-
nducible signaling molecule that, to date, has been
inked primarily to negative feedback regulation of cy-
okine action, particularly interleukin (IL)-6 action on
acrophages and T cells.32,33 Given the unexpected an-
ifibrogenic actions of GH and its induction of SOCS-3,
ollow-up studies were performed in intestinal myofibro-
lasts to examine directly whether GH induces SOCS-3
n intestinal mesenchymal cells and to test whether
OCS-3 negatively modulates the effects of GH or IGF-I
n collagen accumulation. Increasing evidence suggests a
ole for tumor necrosis factor  (TNF) in inflammation-
nduced fibrosis in other organs including lung and
idney34,35 and that TNF is a key proinflammatory
ediator in CD.28 Therefore, we tested whether SOCS-3
nfluenced TNF action on collagen accumulation in
ntestinal myofibroblasts.
Materials and Methods
Bacterial Cell Wall Preparation
PG-APS fragments from cell walls of group A, type 3,
train D58 streptococci (Streptococcus pyogenes) were isolated and
repared as previously described.36 The preparation was soni-
ated immediately before use to disperse aggregates. The final
G-APS concentration based on rhamnose measurements was
2 mg/mL.
Experimental Protocol
Female inbred specific pathogen-free Lewis rats (140–
70 g) were obtained from Charles River Laboratories (Raleigh,
C). All animals were housed in standard cages with 6 animals
er cage and were allowed food and water ad libitum. All animal
rocedures were approved by the Institutional Animal Care and
se Committee of the University of North Carolina at Chapel
ill and conformed to National Institutes of Health guidelines.
nimals were anesthetized with 1.5 mL/kg body weight Innovar
Pitman-Moore, Washington Crossing, NJ) and 80 mg/kg body



































































































206 THEISS ET AL GASTROENTEROLOGY Vol. 129, No. 1y laparotomy using aseptic technique. A total of 24 rats were
njected subserosally with PG-APS (12.5 g rhamnose/g body
eight) into 7 sites of the distal ileum and cecum. A control
roup of rats (n  16) were injected with human serum albumin
HSA; 37.5 g/g body weight, Baxter Healthcare Corporation,
lendale, CA). The rats were monitored for arthritis and were
eighed daily. Of the 24 rats injected with PG-APS, 16 rats
howed spontaneous reactivation of a chronic inflammatory re-
ponse to PG-APS indicated by an increase in joint diameter of .6
m from the previous measurement accompanied by edema and
edness in 1 or both hind ankle joints. On the day of reactivation,
ats were implanted with osmotic minipumps (Durect Corpora-
ion, Cupertino, CA) to administer rhGH (500 g/kg body
eight/day, Genentech Inc., San Francisco, CA) or vehicle (saline)
or 14 days. The dose of GH was chosen to match the low doses
eported in the literature for clinical trials in humans.17 This dose
s at the low end of a range of doses of GH tested for effects on the
ntestine in rodent models.21,22,37,38 PG-APS–injected rats show-
ng reactivation were paired based on comparable joint diameter
t onset of reactivation and one of each pair was administered GH
nd the other was administered vehicle. The aim in pairing
nimals for comparable joint diameter was to minimize any
otential effects of differences in disease severity at the onset of
reatment. An experienced laboratory research analyst assigned
he paired animals to vehicle or GH treatment groups and as-
igned a code number to each animal such that experimenters
erforming all subsequent analyses and evaluation or scoring of
isease severity were blinded to the treatment groups. A total of
pairs of GH-treated and vehicle-treated PG-APS–injected rats
ere studied. HSA control rats were administered GH (n  8) or
ehicle (n  8) in parallel with PG-APS–treated groups. Joint
iameter and body weight were monitored daily throughout the
xperiment. After the 14-day treatment period, rats were killed
y an intramuscular injection of sodium pentobarbital (100 g/g
ody weight, Abbot Laboratories, Chicago, IL). The abdomen was
pened by a midline incision and a gross gut disease score was
erived as one measure of disease severity. Well-established cri-
eria for gross gut disease score have been detailed in previous
eports using the PG-APS model.39 Briefly, 4 independent pa-
ameters consisting of extent of cecal wall thickening, severity of
dhesions, severity of mesenteric contractions, and number of
ecal nodules were each given a score ranging from 0 to 4, where
indicates the most severe disease. The scores for each parameter
ere totaled to derive an overall gross gut disease score, with a
aximum possible score of 16.39
Sample Collection
Blood was collected by cardiac puncture for hemato-
ogic assays (performed by the Animal Clinical Core Facility at
he University of North Carolina). Plasma was separated by
entrifugation and plasma IGF-I concentrations were measured
y enzyme-linked immunosorbent assay (Diagnostic Systems
aboratories Inc., Webster, TX). Samples were pretreated as
escribed in the enzyme-linked immunosorbent assay protocol
o remove IGF-binding proteins complexed to IGF-I. Briefly,
nzyme-linked immunosorbent assay samples were incubated Nith biotin-labeled rat IGF-I and goat anti-rat IGF-I anti-
erum in wells coated with rabbit anti-goat  globulin. Un-
abeled IGF-I in plasma and biotin-labeled IGF-I compete for
imited anti-rat IGF-I binding sites. Streptavidin–horseradish
eroxidase binds the antibody-free biotinylated rat IGF-I,
hose concentration in standards and each sample is estimated
ased on enzymatic turnover of the substrate tetramethylben-
idine and absorbance at 450 and 620 nm.
The entire cecum was dissected and the contents were
ushed with ice-cold .9% saline. The cecal tip was embedded
n frozen tissue–embedding medium (Fisher Scientific, Fair
awn, NJ) for in situ hybridization histochemistry. Adjacent
amples were formalin-fixed and paraffin-embedded; sections
ere used for histologic evaluation of inflammation and fibro-
is. The remaining cecum was cut longitudinally into 2 por-
ions and homogenized immediately in 4 mol/L guanidine
hiocyanate for RNA extraction or in protein extraction buffer
50 mmol/L Hepes, 150 mmol/L NaCl, 20 mmol/L Na pyro-
hosphate, 100 mmol/L NaF, 1.5% Triton X-100, and 100
mol/L ethylenediaminetetraacetic acid containing protease
nhibitors: 1 g/mL aprotinin, 1 mmol/L phenylmethylsulfo-
yl fluoride, and 2 mmol/L vanadate; pH 7.4).
Histologic Scoring of Inflammation and
Fibrosis
Coded paraffin-embedded, formalin-fixed sections of
ecum were stained with H&E, Masson’s trichrome, or Sirius
ed. H&E-stained sections were used to obtain a histologic
core for inflammation using criteria previously described.27,39
score ranging from 0 to 4 (4 being the most severe) was
ssigned for both acute and chronic inflammation of each layer
f the cecal wall. The acute and chronic scores were summed to
erive an overall inflammatory score for each rat, and the
aximum possible score was 32. The acute inflammatory score
as based on hemorrhage, edema, polymorphonuclear leuko-
ytic infiltration, and necrosis. The chronic inflammatory score
as based on the number of mononuclear cells present.
Masson’s trichrome– and Sirius red–stained sections of ce-
um were used to obtain a histologic score for fibrosis. Mas-
on’s trichrome stains collagen, whereas Sirius red stains only
brillar collagen. Experimental sections were compared with
ections from normal untreated control rats to derive a score
anging from 0 to 5 for increases in collagen deposition where
represents no increase and 1–5 represent a progressive in-
rease in collagen in different layers of the cecal wall (Table 1).
score of 5 is the most severe fibrosis representing increased
ollagen deposition throughout all layers from mucosa to
erosa (Table 1). The fibrosis score was multiplied by 1–4 to
eflect 0%–100% extent of the section exhibiting fibrosis. At
east 2 sections of cecum per animal were scored.
Total RNA Extraction and Northern Blot
Hybridization Assays
Total RNA was prepared by the guanidine thiocya-




















































































July 2005 GH REDUCES INTESTINAL FIBROSIS 207cribed40 using 32P-deoxycytidine triphosphate–labeled com-
lementary DNA probes (Random Primed DNA Labeling
it; Roche Diagnostics Corporation, Indianapolis, IN) specific
or rat procollagen 1(I)25, rat TNF (a generous gift of Dr
arl Decker, University of Freiburg, Freiburg, Germany), and
ouse SOCS-3 (a generous gift of Dr Douglas Hilton, The
alter and Eliza Hall Institute of Medical Research, Victoria,
ustralia). 32P-uridine triphosphate–labeled mouse IL-1 and
at IGF-I antisense RNAs also were used as probes.41 To
ccount for minor variations in RNA loading across samples,
lots were reprobed for rat glyceraldehyde-3-phosphate dehy-
rogenase (GAPDH) messenger RNA (mRNA) by using an
ntisense RNA probe prepared from a commercially available
NA template (Ambion Inc., Austin, TX). Blots were scanned
n a Molecular Dynamics Storm 840 Phosphorimager and
RNA abundance was quantified using Image Quant software
version 1.2) for Macintosh (Amersham Biosciences, Piscat-
way, NJ). The abundance of each test mRNA was normalized
o the abundance of GAPDH mRNA in each sample.
Western Immunoblot and
Immunoprecipitation
A total of 100 g cecal protein extracts were separated
n 7.5% polyacrylamide reducing gels followed by semidry
ransfer onto polyvinylidene difluoride membranes (Millipore,
illerica, MA) and blocked in .1% casein and .2 phosphate-
uffered saline. Blots then were immunoblotted with a rabbit
ntibody specific for procollagen 1(I) (Rockland, Gilberts-
ille, PA) and incubated with a goat anti-rabbit secondary
ntibody conjugated to an infrared dye (IR Dye 800 Conju-
ated Goat Anti-Rabbit IgG; Rockland) at a 1:5000 dilution
nd signal visualized using the Odyssey Infrared Imaging
ystem (Li-Cor Biosciences, Lincoln, NE). The infrared-conju-
able 1. Criteria for Histologic Fibrosis Score of Intestine
Score Description
ibrosis 0 No increased collagen deposition
1 Increased collagen deposition in
submucosa
2 Increased collagen deposition in
submucosa and mucosa









5 Increased collagen deposition
throughout all layers including
serosa
ercent involvement 1 0–25% of section
2 25–50% of section
3 50–75% of section
4 75–100% of sectionated secondary antibody allows detection of signal without Ssing the chemiluminescence detection method. Instead, the
dyssey System uses excitatory lasers, enabling fluorescence
etection of the infrared-labeled secondary antibody. The ben-
fits of using the Odyssey system vs chemiluminescence in-
lude detection of proteins across a wide linear range without
he limitation of enzyme/substrate kinetics and greater sensi-
ivity. The signal was quantified using the Odyssey Infrared
maging System Application software version 1.2 (Li-Cor Bio-
ciences). Subsequent blotting with actin antibody (Sigma, St.
ouis, MO) was performed to control for differences in protein
oading.
SOCS-3 was immunoprecipitated from 500 g cecal protein
xtracts with 1 g goat anti–SOCS-3 antibody (Santa Cruz
iotechnology, Santa Cruz, CA) and 20 L 50% protein G
garose beads (Sigma). Nonspecific proteins were removed by
ashing 2 times in cold protein extraction buffer. The samples
ere heated in Promega (Madison, WI) 2 loading buffer at
00°C for 5 minutes and separated in 12.5% polyacrylamide
educing gels followed by semidry transfer onto polyvinylidene
ifluoride membranes. Membranes were blocked in .1% casein
nd .2 phosphate-buffered saline and immunoblotted with a
abbit anti–SOCS-3 antibody (a generous gift of Dr Douglas
ilton). Blots then were incubated with the goat anti-rabbit
econdary antibody conjugated to an infrared dye and signal
isualized using the Odyssey Infrared Imaging System. Im-
unoprecipitation followed by Western immunoblotting for
OCS-3 was performed because Western immunoblotting
lone lacked the sensitivity needed to detect SOCS-3 in cecal
rotein extracts. Complete SOCS-3 recovery was ensured by
ollow-up immunoprecipitation of the cecal extracts with ad-
itional primary antibody and Western analysis.
In Situ Hybridization Histochemistry
Antisense and sense SOCS-3 RNA probes were gener-
ted by polymerase chain reaction using primers described by
osell et al,42 with the addition of a T7 RNA polymerase site
= to the antisense primer and a SP6 RNA polymerase site 5=
o the sense primer. Polymerase chain reaction products were
sed as a complementary DNA template to generate 35S–
ridine triphosphate–labeled sense and antisense RNA probes
sing either SP6 or T7 RNA polymerases, respectively. In situ
ybridization was performed on 10-m cryostat sections of
ecum that were processed as previously described6 with some
odifications. Briefly, frozen sections were fixed in 4% para-
ormaldehyde, treated with proteinase K (.5 g/mL), and
cetylated with triethanolamine (.1 mol/L) and .25% (vol/vol)
cetic anhydride. Sections were prehybridized for 1 hour at
2°C in hybridization buffer containing 75% formamide. Sec-
ions were hybridized with 35S–uridine triphosphate–labeled
robes in hybridization buffer for 18 hours at 62°C in a
umidified chamber, treated with RNase, and washed in low-
alt buffers at 62°C. Slides were exposed to NTB-2 emulsion
Kodak, Rochester, NY) for 14 days at 4°C, developed with






































































































208 THEISS ET AL GASTROENTEROLOGY Vol. 129, No. 1ination. Adjacent sections were stained with Sirius red to
ocalize collagen and H&E for histology.
In Vitro Analyses
Mouse intestinal myofibroblasts were used to evaluate
irectly the effect of GH, IGF-I, and TNF on collagen
ccumulation and the possible modulation of their actions by
verexpression of SOCS-3. Mouse, rather than rat, intestinal
yofibroblasts were used because mouse-derived cells have
roved easier to transfect. Methods for preparation of early
assage cultures of mouse intestinal myofibroblasts were mod-
fied from previously described methods used to isolate rat
ntestinal myofibroblasts.25 Briefly, adult (40- to 50-day old)
ice were killed and the ileum was dissected and washed in
ulbecco’s modified essential medium plus antibiotics (100
/mL penicillin and 50 g/mL streptomycin). Whole-tissue
ieces were washed repeatedly by pipetting into suspension
nd collection by centrifugation. After the final wash, the
issue pieces were resuspended in 5 mL Dulbecco’s modified
ssential medium plus collagenase (300 U/mL CLS-1; Worth-
ngton, Lakewood, NJ) and dispase (.1 mg/mL; Roche Diag-
ostics Corporation) and placed on an orbital shaker (80 cycles/
in) for 25 minutes at room temperature. Two volumes of
ulbecco’s modified essential medium plus 10% fetal bovine
erum then were added and the cell slurry was dispersed by
igorous pipetting. The cell slurry was allowed to settle and
he supernatant was collected and centrifuged. The superna-
ant was discarded and the cell pellet was washed in Dulbecco’s
odified essential medium plus 10% fetal bovine serum and
lated into a T-75 tissue culture flask in the same medium.
edium was changed after 48 hours to remove nonadherent/
ead cells. Adherent cells were maintained in medium plus
0% fetal bovine serum with media changes biweekly. Myo-
broblast phenotype was confirmed based on positive expres-
ion for vimentin and -smooth muscle actin as evaluated by
estern immunoblot.25,43 Subconfluent cells were studied at
assages 3–8.
Intestinal myofibroblasts were serum deprived and treated
ith GH (109 mol/L), TNF (1 ng/mL), IL-6 (10 ng/mL),
L-10 (10 ng/mL), or PG-APS (20 g/mL) alone or in com-
ination with GH for 60 minutes. Doses of GH and PG-APS
ere based on maximal responses found by a dose response
data not shown). Doses of TNF, IL-6, and IL-10 were based
n maximal doses reported in other studies and the duration
as chosen based on the time course of SOCS-3 induction by
H or IL-6 in other cell types.44–46 Total RNA was extracted
sing TRIzol Reagent (Invitrogen, Carlsbad, CA). SOCS-3
RNA abundance was determined by Northern blot hybrid-
zation as described earlier.
We previously have reported direct effects of GH and IGF-I
o stimulate collagen accumulation in cultured intestinal myo-
broblasts.24 In the present study, intestinal myofibroblasts
ere transfected with a human pBIG2i-FLAGSOCS-3 expres-
ion vector or empty vector provided by Dr Richard Furlanetto
University of Rochester School of Medicine and Dentistry,
ew York, NY). pBIG2i-FLAGSOCS-3 contains the complete 	oding sequence of human SOCS-3 with a FLAG-tag epitope
t the amino terminus. The empty vector is identical except
hat it lacks the inserted SOCS-3 coding sequence. Both
ectors were purified by using an endotoxin-free plasmid kit
Qiagen, Valencia, CA). Cells were transfected with empty
ector or pBIG2i-FLAGSOCS-3 using Effectene transfection
eagent (Qiagen) and selected continuously with media con-
aining 100 g/mL Hygromycin B (Roche). Stable transfec-
ants maintained their myofibroblast phenotype, as indicated
y positive expression for vimentin and -smooth muscle
ctin. Transfected cells were serum deprived and treated with
hGH (1010 mol/L), human IGF-I (20 ng/mL), or mouse
NF (1 ng/mL) and compared with no-treatment control
ells. TNF was tested as well as IGF-I because of increasing
vidence for profibrogenic actions of TNF in animal models
f inflammation-induced fibrosis of other organs34,35 and be-
ause of the established role of TNF as a proinflammatory
ediator in CD28 and the PG-APS model. Reverse-transcrip-
ion polymerase chain reaction verified overexpression of
OCS-3 in myofibroblasts transfected with the SOCS-3 expres-
ion vector (data not shown). Collagen accumulation in total
ell lysates was determined by Western immunoblot. Cells
ere solubilized in sodium dodecyl sulfate sample buffer and
ize fractionated on 8.5% sodium dodecyl sulfate–polyacryl-
mide gels and transferred onto polyvinylidene difluoride
embranes (Millipore). Blots were blocked in phosphate-buff-
red saline containing 3% nonfat dry milk and incubated for
6 hours at 4°C with a rabbit polyclonal antibody specific for
rocollagen 1(I) (Rockland). Blots were washed and then
xposed to peroxidase-conjugated secondary antibody for 1
our at room temperature. Blots were washed and immunore-
ctive proteins were detected by using an enhanced chemilu-
inescence detection system (Amersham, Piscataway, NJ).
lots were reprobed with rabbit polyclonal anti-actin as a
oading control (Sigma). Radiograph films were analyzed by
ensitometry and signal intensity for procollagen 1(I), or
oading control was quantified using National Institutes of
ealth image software (version 1.61; available at: http://rsb.
nfo.nih.gov/nih-image/).
Statistical Analyses
Values are expressed as mean  SEM. Data from in
ivo experiments were analyzed by 2-way analysis of variance
o test for significant effects of PG-APS or GH, and a signif-
cant interaction between PG-APS and GH, which provides
tatistical evidence for an effect of GH on the response to
G-APS. Subsequent pair-wise comparisons used Tukey’s post
oc test to test for significant differences between 2 particular
roups. Linear regression analyses were performed to test for
ossible correlations between particular parameters measured.
ata from in vitro experiments were compared by 1-way
nalysis of variance for significant effects of treatments vs
ontrol followed by planned pairwise comparisons. A P value








































































July 2005 GH REDUCES INTESTINAL FIBROSIS 209Results
GH Reduces Gross Intestinal Injury and
Joint Inflammation During PG-APS–Induced
Colitis
We previously established that increased joint
iameter provides a reliable and readily measurable sign
f reactivation and progression of chronic inflammation
nd enterocolitis in the PG-APS model.26 In this study,
he diameter of both hind ankle joints was measured
aily to monitor reactivation and as an overt measure of
isease severity over the course of GH or vehicle treat-
ent. Joint diameter at the onset of reactivation in
G-APS–injected rats was comparable in animals as-
igned to GH (15.26  .38 mm, pooled left and right
oints) or vehicle (15.45  .35 mm) treatment groups
nd was significantly higher than in control animals
njected with HSA and assigned to vehicle (13.32  .16
m) or GH (13.08  .15 mm; P 	 .05) groups. Figure
shows the mean percentage change in joint diameter
rom start of vehicle or GH infusion to the end of the
4-day infusion period. HSA control animals showed no
igns of inflammation or redness and only small increases
n joint diameter, which are typical of normal growth,
nd did not differ significantly between vehicle- and
H-treated rats over the course of the 14-day treatment
Figure 1). PG-APS–injected rats showed significant in-
reases in joint diameter typical of the worsening joint
nflammation as chronic inflammation progressed. PG-
PS–injected animals given GH showed significantly
maller increases in joint diameter compared with vehi-
igure 1. Mean percent change in joint diameter during GH or vehicle
nfusion in HSA- and PG-APS–injected rats. Values are mean  SEM of
ercent joint diameter change in each animal after 14 days of infusion
ith GH or vehicle relative to diameter at the start of GH or vehicle (v)
nfusion. aP 	 .005 vs HSA controls; bP 	 .05 vs PG-APS 
 V.le-treated PG-APS–injected animals (Figure 1). bBody weight, white blood cell count, and hemoglobin
oncentration were used as clinical measures of disease
Table 2). As a group, HSA-injected rats gained more
eight than PG-APS–injected rats during the 14-day
nfusion period (7.6%  1.5% HSA combined vehicle
nd GH vs 2.1%  1.5% PG-APS; P 	 .05). When
eparated into vehicle or GH treatment groups, GH did
ot significantly increase body weight gain in either
SA- or PG-APS–injected rats compared with vehicle
Table 2). PG-APS–injected rats showed increased white
lood cell counts and reduced hemoglobin concentra-
ions, which are typical signs of disease in this model,39
nd GH did not alter these measures of inflammation.
HSA control rats given vehicle or GH had little or no
ross evidence of intestinal injury, as indicated by low
ross gut disease scores (Table 3). PG-APS rats showed
xtensive adhesions, mesentery contractions, cecal wall
hickening, cecal nodules, and hepatic nodules (Table 3).
G-APS rats administered GH had small but significant
eductions in gross disease score compared with PG-
PS–injected rats given vehicle (Table 3). Significantly
ower mean scores for adhesions and mesentery contrac-
ions, which are 2 complications of intestinal fibrosis,
rimarily contributed to the lower gross injury scores in
H-treated PG-APS–injected rats (Table 3).
Modest Reductions in Histologic and
Biochemical Measures of Fibrosis in
GH-Treated Rats
Bright-field photomicrographs of representative
ecum sections stained with Sirius red for collagen are
hown in Figure 2. Mean, blinded histologic scores for
everity of fibrosis in cecum sections stained with Sirius
ed or Masson’s trichrome are shown in Table 4. HSA
ontrol rats treated with vehicle or GH had low fibrosis
cores (	1.0) with the majority of collagen deposition
ocated within the submucosa, as is found in the normal
ecum (Figures 2A and B). PG-APS rats showed obvious
able 2. Percent Body Weight Change and Hematologic
Profile in Rats Injected With PG-APS or HSA and








 V 6.7  1.4 5.2  .4 16.5  .2
SA 
 GH 8.3  1.3 7.4  1.1 15.5  .8
G-APS 
 V 1.4  1.8b 19.3  1.9a 13.4  .3b
G-APS 
 GH 2.8  2.4 17.9  1.9a 12.6  .6a
OTE. Values are expressed as mean  SEM. n  8 animals in each
reatment group.
BC, white blood cells; V, vehicle.
P 	 .001 vs HSA controls.






















210 THEISS ET AL GASTROENTEROLOGY Vol. 129, No. 1ncreases in transmural collagen deposition (Figures 2C–
), validated by significant increases in mean histologic
cores for fibrosis (Table 4). PG-APS rats treated with
H had a modest but significant reduction in histologic
cores for fibrosis (Table 4) compared with PG-APS–
njected rats given vehicle (Table 4), as shown also by the
able 3. Gross Findings of Rats Injected With HSA or PG-APS




 V .2  .2 .1  .1
SA 
 GH .1  .1 .1  .1
G-APS 
 V 10.0  .9a 2.9  .4a 3
G-APS 
 GH 8.0  .4a,b 1.7  .3a,c 2
OTE. Values are expressed as mean  SEM. n  8 animals in eac
, vehicle.
P 	 .001 vs HSA controls.
P 	 .05 vs PG-APS 
 V.
P 	 .01 vs PG-APS 
 V.epresentative sections in Figures 2C and E vs Figure 2D
nd F.
Expression of procollagen 1(I) mRNA and protein in
ecal extracts were assayed as biochemical markers of
brosis. GH had no effect on collagen mRNA or protein
bundance in HSA control rats. However, during PG-




thickening Cecal nodules Liver nodules
.1 .0  .0 .0  .0 .0  .0
.0 .0  .0 .0  .0 .0  .0
.3a 2.1  .2a 2.0  .3a 2.5  .4a
.4a,b 1.9  .1a 2.2  .3a 1.7  .3a
tment group.
Figure 2. Representative bright-
field photomicrographs of sec-
tions of cecum stained with
Sirius red for collagen. (A) HSA

 vehicle; (B) HSA 
 GH; (C, E)
PG-APS 





















































July 2005 GH REDUCES INTESTINAL FIBROSIS 211PS–induced colitis, GH modestly reduced collagen
RNA (Figure 3A) and protein (Figure 3B) abundance
ompared with vehicle control rats. Regression analysis
evealed highly significant correlations in individual an-
mals across the independent measures of fibrosis, indi-
ating consistent results: cecal collagen mRNA vs histo-
ogic fibrosis scores (r  .66; P 	 .01), cecal collagen
RNA vs cecal collagen protein (r  .70; P 	 .005),
ecal collagen protein vs histologic fibrosis scores (r 
51; P 	 .05).
able 4. Fibrosis Scoring of Rat Cecum Injected With HSA
or PG-APS and Administered Vehicle or GH
Fibrosis score
SA 
 V .3  .1
SA 
 GH .7  .2
G-APS 
 V 9.7  .5a
G-APS 
 GH 7.9  .5a,b
OTE. Values are expressed as mean  SEM. n  8 animals in each
reatment group. Scores reflect evaluation of 4 sections of cecum for
ach animal.
, vehicle.
P 	 .001 vs HSA controls.
P 	 .05 vs PG-APS 
 V.
igure 3. (A) Representative Northern blots showing procollagen 1(I
nd (B) representative Western immunoblots for procollagen 1(I)
reatments are indicated. Histograms showing mean  SEM of the fo
n the same blot. aP 	 .005 vs HSA controls, bP 	 .05 vs PG-APS 
 V.GH Treatment Does Not Affect Severity of
Inflammation in the Cecum
To determine if effects of GH on fibrosis were
ssociated with effects on intestinal inflammation, sever-
ty of colitis in the cecum was measured by an established
linded scoring system for acute and chronic inflamma-
ion.27,39 PG-APS–injected rats showed dramatic in-
reases in scores for acute and chronic intestinal inflam-
ation compared with HSA controls (Table 5). GH
reatment had no significant effect on acute or chronic
nflammation scores in either HSA- or PG-APS–injected
ats (Table 5).
Expression of IL-1 and TNF mRNA, two proin-
ammatory cytokines known to be up-regulated at the
RNA level in the PG-APS model, also were quan-
ified as independent biochemical markers of inflam-
ation. Figure 4 shows representative Northern blots
f IL-1 and TNF mRNA expression in the cecum of
SA and PG-APS rats treated with vehicle or GH.
G-APS–injected rats had significantly increased lev-
ls of cecal IL-1 and TNF mRNAs. GH treatment
ad no significant effect on IL-1 or TNF mRNA
bundance in cecum of PG-APS–injected rats. Histo-
control (GAPDH) mRNA abundance in total RNA isolated from cecum
in and actin protein as a loading control in cecal protein extracts.
erence relative to the mean value of HSA 




































212 THEISS ET AL GASTROENTEROLOGY Vol. 129, No. 1ogic inflammatory scores were correlated directly
ith IL-1 expression (r  .47; P 	 .05) and TNF
xpression (r  .51; P 	 .05) in individual animals,
ndicating consistent results from independent histo-
ogic and biochemical measures.
able 5. Histologic Scoring of Inflammation in Cecum
Sections Stained With H&E From Rats Injected












 V .8  .2 .0  .0 .8  .2
SA 
 GH .9  .4 .0  .0 .9  .4
G-APS 
 V 9.1  .9a 2.2  .5a 6.7  .3a
G-APS 
 GH 9.7  .8a 3.1  .6a 6.9  .3a
OTE. Values are expressed as mean  SEM. n  8 animals in each
reatment group. Scores reflect evaluation of 2 sections of cecum for
ach animal.
, vehicle.
P 	 .001 vs HSA controls.
igure 4. Representative Northern blots showing (A) IL-1 and (B
G-APS–injected rats treated with vehicle or GH. Histograms showing
ehicle controls analyzed on the same blot. aP 	 .05 vs HSA controls.Plasma Levels of IGF-I and Cecal
Expression of IGF-I
Because many actions of GH are mediated by
GF-I, plasma IGF-I and local IGF-I expression in the
ecum were measured to determine if the effects of GH
n fibrosis or joint diameter were related to altered
GF-I. Plasma IGF-I concentration was increased signif-
cantly by approximately 50% during PG-APS–induced
nflammation compared with controls (Table 6). GH
reatment caused no further increase in plasma IGF-I
F and control (GAPDH) mRNA expression in cecums of HSA- or
n  SEM of the fold-difference relative to the mean value of HSA 

able 6. Concentration of Plasma IGF-I in Rats Injected With




 V 1102.9  49.2
SA 
 GH 1063.6  50.3
G-APS 
 V 1550.3  97.0a
G-APS 
 GH 1405.5  50.8a
OTE. Values are expressed as mean  SEM. n  8 animals in each
reatment group, performed in duplicate. V, vehicle.




























































July 2005 GH REDUCES INTESTINAL FIBROSIS 213evels in PG-APS–injected rats and did not significantly
lter plasma IGF-I concentrations in HSA-injected rats.
bundance of cecal IGF-I mRNA was increased during
G-APS–induced colitis as shown previously in this
nimal model,29 but did not differ in GH vs vehicle-
reated rats (Figure 5).
GH Increases SOCS-3 mRNA and Protein
Abundance During PG-APS–Induced Colitis
Expression of SOCS-3, which has been implicated
s a negative regulator of intestinal inflammation,47 was
ssessed by Northern blot hybridization in total cecal
NA. SOCS-3 mRNA abundance was increased by
-fold in PG-APS–injected rats that were administered
H (P 	 .005) compared with PG-APS–injected rats
igure 5. (A) Representative Northern blot showing IGF-I and control
GAPDH) mRNA expression in total RNA isolated from cecum. Treat-
ents are indicated. (B) Histograms showing mean  SEM of the
old-difference relative to the mean value of HSA 
 vehicle controls
nalyzed on the same blot. aP 	 .05 vs HSA controls.iven vehicle, but was not increased significantly in bH-treated HSA-injected rats relative to vehicle control
SA rats (Figure 6A). SOCS-3 protein also was increased
n GH-treated PG-APS–injected rats compared with
ehicle-treated rats (Figure 6B). Linear regression analy-
is revealed that SOCS-3 mRNA abundance showed a
ignificant inverse correlation with histologic fibrosis
core (r  .74; P 	 .05) and cecal collagen mRNA
bundance (r  .69; P 	 .05) in individual PG-APS–
reated rats, and SOCS-3 protein abundance showed a
ignificant inverse correlation with cecal collagen protein
r  .62; P 	 .05), providing indirect evidence that
ncreased SOCS-3 expression induced by GH during
G-APS–induced colitis could contribute to GH-depen-
ent reduction in intestinal fibrosis. In HSA-injected
ontrol rats, there was no significant correlation between
OCS-3 mRNA levels and cecal fibrosis score (r  .02;
 .51) or collagen mRNA expression (r  .04; P 
89), indicating that the inverse association between
OCS-3 and fibrosis occurs only during inflammation.
nalyses of SOCS-1 and SOCS-2 mRNAs, other mem-
ers of the family of suppressor of cytokine signaling
nown to be induced in intestine by GH in some set-
ings,48 revealed very low constitutive expression and no
nduction by GH in HSA- or PG-APS–injected rats in
otal RNA isolated from cecum (data not shown).
SOCS-3 mRNA Localizes to the Periphery of
Granulomas
In situ hybridization on cecal sections from PG-
PS– and GH-treated rats localized SOCS-3 mRNA to the
eriphery of serosal granulomas (Figure 7E and F), corre-
ating with sites of collagen accumulation visualized by
irius red staining (compare Figure 7C and E). In adjacent
ections, SOCS-3 sense control was negative, validating the
pecificity of hybridization signals obtained with the anti-
ense probe. Cells at the periphery of granulomas in the
G-APS model were previously characterized as myofibro-
lasts25 that deposit collagen protein, resulting in collagen
urrounding the granuloma. SOCS-3 mRNA was barely
etected in cecum of PG-APS given vehicle and HSA
ontrol animals, and expression could not be attributed
onclusively to specific cell populations (data not shown).
GH in Combination With TNF, IL-6, IL-10,
or PG-APS Rapidly Up-Regulates SOCS-3
mRNA Abundance in Cultured Intestinal
Myofibroblasts
Cultured intestinal myofibroblasts were treated
ith GH, TNF, IL-6, IL-10, and PG-APS, alone or in
ombination with GH, to determine which factors in-
uce SOCS-3 expression in cultured intestinal myofibro-













































214 THEISS ET AL GASTROENTEROLOGY Vol. 129, No. 1OCS-3 mRNA abundance, but TNF, IL-6, IL-10, and
G-APS, when given in combination with GH, all in-
uced SOCS-3 expression (Figure 8).
GH, IGF-I, and TNF Induce Collagen
Accumulation in Cultured Intestinal
Myofibroblasts and SOCS-3 Inhibits This
Effect
To test whether SOCS-3 can modulate GH action
n collagen accumulation, intestinal myofibroblasts sta-
ly transfected with a SOCS-3 expression vector or
mpty vector control were treated with GH. GH ro-
ustly stimulated collagen accumulation in empty vec-
or–transfected cells and this effect was attenuated in
OCS-3–overexpressing cells (Figure 9). The effect of
OCS-3 was not limited to GH because IGF-I and TNF
ach induced collagen accumulation in empty vector–
ransfected cells, but SOCS-3 overexpression attenuated
he effects of GH and IGF-I and eliminated the effects of
NF (Figure 9).
Discussion
Prior studies in animal models have indicated that
igure 6. (A) Representative Northern blot showing SOCS-3 and cont
reated with vehicle or GH. Values are mean  SEM of SOCS-3 mRN
f HSA 
 vehicle controls analyzed on the same blot. aP 	 .005. (B) R
xtracts immunoprecipitated for SOCS-3. Omission of primary antibod
rotein isolated from Caco-2 cells transfected with a SOCS-3 expressio
ith empty vector (E). Histograms showing mean  SEM of the fold-di
n the same blot. aP 	 .05 vs PG-APS 
 V.H promotes mucosal repair after chemically induced aucosal damage and acute intestinal inflammation.21,23
ur study showed that GH does not exacerbate fibrosis
ssociated with chronic PG-APS–induced transmural
ranulomatous enterocolitis. Rather, GH moderately re-
uced gross complications of inflammation associated
ith fibrosis such as adhesions and mesentery contrac-
ions and modestly reduced histologic and biochemical
easures of fibrosis. These results of GH infusion in an
nimal model of chronic enterocolitis and fibrosis are
eassuring with respect to potential complications of GH
herapy in patients with IBD because they provide no
vidence that GH worsens fibrosis, a serious complica-
ion that is common in patients with CD.
A second experiment in a small number of animals
sing an entirely different preparation of PG-APS re-
ealed similar effects of GH to reduce gross gut scores for
dhesions (vehicle, 3.5  .5; vs GH, 1.5  .5) and
esentery contractions (vehicle, 3.0  .0; vs GH, 1.5 
5), as well as histologic fibrosis score (vehicle, 11.7  .4;
s GH, 8.9  .5), validating the reproducibility of the
ntifibrogenic effects of GH. The reduced fibrosis in
H-treated rats could represent decreased synthesis and
eposition of collagen, decreased myofibroblast prolifer-
APDH) mRNA expression in cecums of HSA- or PG-APS–injected rats
ndance normalized to GAPDH expression relative to the mean value
sentative Western immunoblot for SOCS-3 protein from cecal protein
ng the immunoprecipitation was performed as a negative control ().
tor was used as a positive control (3) compared with cells transfected
ce relative to the mean value of PG-APS 








































July 2005 GH REDUCES INTESTINAL FIBROSIS 215RNA, protein, and histologic fibrosis scores in GH-
reated rats supports an effect on collagen synthesis and
ccumulation. We did not evaluate directly the effects of
H on proliferation of mesenchymal cells at sites of
ollagen deposition. Attempts to identify proliferating
esenchymal cells by bromodeoxyuridine incorporation
r immunostaining have proved problematic (Lund, un-
ublished data, November 2000). This is because it is
ifficult to distinguish mesenchymal cells from numer-
us immune cells labeled with bromodeoxyuridine.
hus, we cannot formally exclude an effect of GH on
esenchymal cell proliferation, although it should be
oted that in cultured myofibroblasts GH has little or no
ffect on proliferation.49 Although the reduction in fi-
rosis by GH was modest, it was verified by 4 different
easures that include gross gut disease scores for adhe-
ions and mesentery contractions, histologic fibrosis
igure 8. Representative Northern blot showing SOCS-3 and control
GAPDH) mRNA expression in cultured intestinal myofibroblasts
reated with GH alone or in combination with various cytokines or
G-APS. Values are mean  SEM of SOCS-3 mRNA abundance nor-
alized to GAPDH expression relative to the mean value of no treat-
ent (No Tx) controls analyzed on the same blot. aP 	 .05 vs noigure 7. (A–D) Bright-field and (E, F) dark-field photomicrographs
how in situ hybridization of SOCS-3 mRNA (E, F) at the periphery of a
ranuloma (inside box) in the serosa of a PG-APS 
 GH rat. (C, D)
OCS-3 mRNA localizes to sites of collagen deposition as revealed in
djacent sections by Sirius red staining. (G, H) A SOCS-3 sense RNA
robe was used as a negative control and gave a negative signal. HE,
&E-stained adjacent section to show histology. SR, Sirius red–
tained adjacent section to indicate localization of collagen protein









































































216 THEISS ET AL GASTROENTEROLOGY Vol. 129, No. 1core, and type I collagen mRNA and protein abundance.
mportantly, these results provide no evidence that GH
ill exacerbate fibrosis in patients with IBD. It is im-
ortant to emphasize that GH was given therapeutically
n a situation of ongoing chronic inflammation. Given
hat few, if any, current treatments are known to reduce
omplications of fibrosis, this effect in an experimental
odel indicates that evaluation of GH action on fibrosis
n humans with SBS or IBD is warranted.
Despite modest beneficial effects of GH on fibrosis,
herapeutic GH had no effect on intestinal inflammation
ssessed by histologic scoring of acute and chronic colitis,
igure 9. (A) Western blots of procollagen 1(I) protein accumulation
nd actin (control) in intestinal myofibroblasts transfected with
OCS-3 (3) or empty vector (E) expression constructs and treated with
H. (B) Western blots showing procollagen 1(I) and control protein
bundance in intestinal myofibroblasts transfected with SOCS-3 or
mpty vector expression constructs and treated with IGF-I or TNF. (C)
rocollagen 1(I) protein abundance normalized to control protein
bundance, relative to no treatment control value (set at 1) analyzed
n the same blot. n  5 per treatment group. aP 	 .05 vs no
reatment control, bP 	 .05 vs empty vector–transfected cells of the
ame treatment.rossly evident cecal wall thickening and granulomas, or Ahe level of expression of IL-1 and TNF. The lack of
ffect of GH on inflammation is consistent with our prior
ndings in GH-transgenic mice in which GH overex-
ression did not alter the severity of inflammation or
ucosal damage induced by dextran sodium sulfate ad-
inistration, although GH-transgenic mice did show
ore rapid epithelial repair and crypt regeneration after
extran sodium sulfate treatment.23 We did not examine
ffects of GH on epithelial responses to PG-APS–in-
uced colitis in the present study, largely because the
G-APS model is one of progressive worsening of
hronic submucosal-predominant inflammation that does
ot lend itself readily to studies of epithelial repair.
owever, the lack of effect of GH on inflammation
ndicates that even if GH did affect the epithelium in
his model, this does not improve the course of chronic
nflammation. Prior studies reporting anti-inflammatory
ctions of GH22 or effects of GH on mucosal repair50
nvolved GH administration before and during the in-
uction of mucosal damage and inflammation. We de-
iberately administered GH therapeutically after the on-
et of chronic inflammation to best mimic the clinical
ctions of GH treatment during active, chronic IBD. The
bsence of an anti-inflammatory effect of GH on the
ntestine when given during active, chronic disease in the
G-APS model, but anti-inflammatory actions when
iven before disease onset, indicates that timing of GH
herapy relative to time of disease onset or remission may
e critical to maximizing the benefits of GH therapy in
D patients.
In the PG-APS model, GH treatment did result in
oderate but significant reductions in the severity of joint
nflammation, indicated by the smaller increase in joint
iameter in GH-treated rats. Thus, GH did improve one of
he extraintestinal inflammatory complications secondary to
G-APS–induced colitis. We did not perform joint histol-
gy or biochemical analysis of joint inflammation in this
tudy, but the induction of SOCS-3 in intestine by GH is
ntriguing given findings that adenovirus therapy with
OCS-3 expression constructs improved arthritis in mouse
odels of antigen-induced and collagen-induced arthritis.51
herefore, GH may improve joint inflammation by induc-
ng SOCS-3 and the study of the effects of GH on SOCS-3
r of other mechanisms of action in joint inflammation in
nimal models of IBD or in patients with IBD is warranted
n the future.
Because many actions of GH are mediated through
GF-I, and IGF-I is implicated as a mediator of fibrosis in
D,1 we had anticipated that GH may increase plasma or
ocal levels of IGF-I and thus indirectly increase collagen
ynthesis or fibrosis during PG-APS–induced colitis. PG-





































































































July 2005 GH REDUCES INTESTINAL FIBROSIS 217ompared with control rats, but GH treatment showed no
ffect compared with vehicle infusion. This lack of response
ould be caused by the relatively low dose of GH used
uring the infusion, which was chosen to more closely
eplicate dosing in humans. In addition, it is well estab-
ished that inflammation leads to a situation of GH resis-
ance in the liver such that GH is unable to induce IGF-I
ynthesis.52 Thus, the absence of an effect of GH to increase
lasma IGF-I or body weight gain likely reflects this phe-
omenon. Cecal expression of IGF-I was increased during
G-APS inflammation, as shown previously,29 but did not
hange with GH treatment. This indicates that systemic
dministration of low doses of GH does not increase local
GF-I expression further in the intestine above the already
ncreased levels associated with chronic intestinal inflam-
ation. This finding is especially important because con-
iderable evidence suggests locally expressed, mesenchymal
ell–derived IGF-I, acting in a paracrine and/or autocrine
anner, may be a mediator of inflammation-induced intes-
inal fibrosis.1
In the liver, SOCS proteins have been shown to be
nduced by GH, and in settings of hepatic or systemic
nflammation to prevent GH induction of IGF-I.52 Re-
ent findings in a rat model of total parenteral nutrition
ndicate that GH induces SOCS-2 in the small intestine
nd colon and that SOCS-2 can limit the proliferative
ctions of GH and IGF-I on the intestinal epithelium.48
e therefore analyzed SOCS expression in cecum of
SA- or PG-APS–injected rats given vehicle or GH with
he rationale that GH induction of SOCS could limit the
brogenic actions of GH or endogenously up-regulated
GF-I that appears to mediate or contribute to fibrosis
uring intestinal inflammation. In contrast to the total
arenteral nutrition model, GH administered to HSA
ontrol rats induced neither SOCS-2 nor SOCS-3
RNA. At present, we have no experimental evidence to
stablish why cecal levels of SOCS-2 were not up-regu-
ated in HSA rats by GH treatment as observed in total
arenteral nutrition controls, except that the dose of GH
as lower and the duration of treatment was longer. In
ddition, oral feeding in the current study vs total par-
nteral nutrition feeding, when GH was found to induce
OCS-2, could impact on GH induction of SOCS.
However, in PG-APS–injected rats, GH robustly in-
uced SOCS-3 mRNA and protein relative to vehicle-
njected controls. This is intriguing because SOCS-3 is
mplicated increasingly as a negative modulator of the
ctions of proinflammatory cytokines on macrophages
nd T cells.32,33 However, in the PG-APS model, GH
nduction of SOCS-3 was not associated with reduced
nflammation, nor did SOCS-3 levels show a significant
egative correlation with measures of inflammation, as cight be anticipated if, in this setting, SOCS-3 had
nti-inflammatory actions. Instead, regression analysis
evealed SOCS-3 mRNA abundance showed a significant
nverse correlation with cecum fibrosis score and collagen
RNA abundance in individual PG-APS–treated rats
nd SOCS-3 protein abundance showed a significant
nverse correlation with collagen protein abundance.
owever, HSA control rats showed no correlation be-
ween SOCS-3 mRNA expression and cecum fibrosis
core or collagen mRNA expression. Furthermore, in situ
ybridization revealed SOCS-3 mRNA localized to the
eriphery of granulomas in PG-APS–injected rats treated
ith GH, indicating SOCS-3 is induced in a relevant cell
opulation. Previous studies have localized GH receptor
xpression in the intestinal mucosa layer and to mesen-
hymal cells in submucosa, muscularis, and serosa lay-
rs,53 consistent with responsiveness of these cells to GH
n vivo. Because it is difficult in in vivo studies to show
irectly that GH induction of SOCS-3 mediates the
eduction in fibrosis, we used simple cell culture models
o test this possibility.
Treatment of intestinal myofibroblasts with GH,
NF, IL-6, IL-10, or PG-APS alone failed to induce
OCS-3 expression. However, GH in combination with
hese factors rapidly induced SOCS-3. These results in-
icate GH, in combination with other cytokines ex-
ressed during inflammation, can up-regulate SOCS-3
xpression in intestinal myofibroblasts, but SOCS-3 is
ot up-regulated when GH is administered alone. This is
mportant mechanistically given our in vivo evidence
hat SOCS-3 induction correlated with reduced fibrosis
nd more direct evidence in cultured myofibroblasts that
OCS-3 overexpression directly inhibited GH-, IGF-I–
r TNF-induced collagen accumulation. These results
upport a model (Figure 10) that induction of SOCS-3
xpression in the inflamed intestine by GH, in combi-
ation with other cytokines, decreases the fibrogenic
ctions of IGF-I and TNF, which are favored as medi-
tors of fibrosis, and therefore SOCS-3 mediates antifi-
rogenic rather than profibrogenic actions of GH. One
urprising finding in the present study was that SOCS-3
RNA expression was not up-regulated in the cecum of
ats with chronic PG-APS–induced enterocolitis vs HSA
ontrols in the absence of GH therapy. This contrasts
ith increases in SOCS-3 expression reported in a num-
er of IBD models, including the dextran sodium sulfate
odel and the IL-10 knockout mouse.47 It seems likely
hat the difference in up-regulation of endogenous
OCS-3 across IBD models reflects variations in chronic-
ty of inflammation and the particular cytokine milieu
ecause it is known that SOCS-3 mRNA is induced







































218 THEISS ET AL GASTROENTEROLOGY Vol. 129, No. 1losely to IL-6 up-regulation in other models.54 None-
heless, our findings that GH induces SOCS-3 in a
hronic granulomatous enterocolitis model that shares
eatures with CD and the new evidence that this induc-
ion inversely correlates with severity of fibrosis, rather
han inflammation, suggest a role of SOCS-3 as an anti-
brogenic signaling intermediate in mesenchymal cells
hat warrants further investigation.
In conclusion, our findings in the PG-APS rat model of
hronic intestinal inflammation and fibrosis indicate that
H treatment does not exacerbate intestinal fibrosis and has
modest therapeutic benefit to decrease intestinal fibrosis
uring chronic disease. These data extend previous findings
uggesting beneficial effects of rhGH used as therapy in
atients with CD and SBS.10–13,16,18–20 Our study of ther-
peutic GH in an animal model of chronic intestinal in-
ammation and fibrosis provides no evidence that GH will
xacerbate fibrosis in IBD, but instead provides new evi-
ence that GH may have antifibrogenic actions mediated by
he induction of SOCS-3 expression.
References
1. Zimmermann E, Lund PK. Fibrogenesis. In: Sartor RB, Sandborn
WJ, eds. Kirsner’s inflammatory bowel diseases. 6th ed. Phila-
delphia: Elsevier, 2004:219–229.
2. Graham MF, Diegelmann RF, Elson CO, Lindblad WJ, Gotschalk N,
Gay S, Gay R. Collagen content and types in the intestinal stric-
tures of Crohn’s disease. Gastroenterology 1988;94:257–265.
3. Matthes H, Herbst H, Schuppan D, Stallmach A, Milani S, Stein H,
Riecken EO. Cellular localization of procollagen gene transcripts
in inflammatory bowel diseases. Gastroenterology 1992;102:
igure 10. Hypothetical model showing PG-APS induction of proin-
ammatory cytokines that, together with therapeutic GH, induce
OCS-3. SOCS-3 decreases the fibrogenic actions of proinflammatory
ytokines including TNF, IGF-I, and GH itself, resulting in decreased
ntestinal fibrosis.431–442.4. Powell DW, Mifflin RC, Valentich JD, Crowe SE, Saada JI, West AB.
Myofibroblasts. II. Intestinal subepithelial myofibroblasts. Am J
Physiol 1999;277:C183–C201.
5. Powell DW, Mifflin RC, Valentich JD, Crowe SE, Saada JI, West AB.
Myofibroblasts. I. Paracrine cells important in health and dis-
ease. Am J Physiol 1999;277:C1–C9.
6. Pucilowska JB, McNaughton KK, Mohapatra NK, Hoyt EC, Zim-
mermann EM, Sartor RB, Lund PK. IGF-I and procollagen alpha1(I)
are coexpressed in a subset of mesenchymal cells in active
Crohn’s disease. Am J Physiol 2000;279:G1307–G1322.
7. Van Assche G, Geboes K, Rutgeerts P. Medical therapy for
Crohn’s disease strictures. Inflamm Bowel Dis 2004;10:55–60.
8. Becker JM. Surgical therapy for ulcerative colitis and Crohn’s
disease. Gastroenterol Clin North Am 1999;28:371–390, viii–ix.
9. Scolapio JS, Camilleri M, Fleming CR, Oenning LV, Burton DD,
Sebo TJ, Batts KP, Kelly DG. Effect of growth hormone, glutamine,
and diet on adaptation in short-bowel syndrome: a randomized,
controlled study. Gastroenterology 1997;113:1074–1081.
0. Ellegard L, Bosaeus I, Nordgren S, Bengtsson BA. Low-dose
recombinant human growth hormone increases body weight and
lean body mass in patients with short bowel syndrome. Ann Surg
1997;225:88–96.
1. Byrne TA, Persinger RL, Young LS, Ziegler TR, Wilmore DW. A new
treatment for patients with short-bowel syndrome. Growth hormone,
glutamine, and a modified diet. Ann Surg 1995;222:243–254.
2. Cukier C, Waitzberg DL, Borges VC, Silva Mde L, Gama-Rodrigues
J, Pinotti HW. Clinical use of growth hormone and glutamine in
short bowel syndrome. Rev Hosp Clin Fac Med Sao Paulo 1999;
54:29–34.
3. Seguy D, Vahedi K, Kapel N, Souberbielle JC, Messing B. Low-
dose growth hormone in adult home parenteral nutrition-depen-
dent short bowel syndrome patients: a positive study. Gastroen-
terology 2003;124:293–302.
4. Szkudlarek J, Jeppesen PB, Mortensen PB. Effect of high dose
growth hormone with glutamine and no change in diet on intestinal
absorption in short bowel patients: a randomised, double blind,
crossover, placebo controlled study. Gut 2000;47:199–205.
5. Scolapio JS. Effect of growth hormone, glutamine, and diet on
body composition in short bowel syndrome: a randomized, con-
trolled study. JPEN J Parenter Enteral Nutr 1999;23:309–313.
6. Byrne TA, Morrissey TB, Nattakom TV, Ziegler TR, Wilmore DW.
Growth hormone, glutamine, and a modified diet enhance nutri-
ent absorption in patients with severe short bowel syndrome.
JPEN J Parenter Enteral Nutr 1995;19:296–302.
7. Scolapio JS. Tales from the crypt. Gastroenterology 2003;124:
561–564.
8. Mauras N, George D, Evans J, Milov D, Abrams S, Rini A, Welch
S, Haymond MW. Growth hormone has anabolic effects in glu-
cocorticosteroid-dependent children with inflammatory bowel dis-
ease: a pilot study. Metabolism 2002;51:127–135.
9. Henker J. Therapy with recombinant growth hormone in children
with Crohn’s disease and growth failure. Eur J Pediatr 1996;155:
1066–1067.
0. Slonim AE, Bulone L, Damore MB, Goldberg T, Wingertzahn MA,
McKinley MJ. A preliminary study of growth hormone therapy for
Crohn’s disease. N Engl J Med 2000;342:1633–1637.
1. Christensen H, Flyvbjerg A, Orskov H, Laurberg S. Effect of growth
hormone on the inflammatory activity of experimental colitis in
rats. Scand J Gastroenterol 1993;28:503–511.
2. Kara E, Sungurtekin H, Sungurtekin U, Alkanat M, Ilkgul O. The
effect of recombinant human growth hormone (rhGH) on trinitro-
benzene sulfonic acid-induced colitis in rats: an experimental
study. Inflamm Bowel Dis 2004;10:112–115.
3. Williams KL, Fuller CR, Dieleman LA, DaCosta CM, Haldeman KM,
Sartor RB, Lund PK. Enhanced survival and mucosal repair after
dextran sodium sulfate-induced colitis in transgenic mice that over-








































July 2005 GH REDUCES INTESTINAL FIBROSIS 2194. Fruchtman S, Simmons JG, Fuller CR, Greenhalgh CJ, Lund PK.
Suppressors of cytokine signaling (SOCS) limit fibrogenic actions
of growth hormone and insulin-like growth factor-I in intestinal
myofibroblasts. Gastroenterology 2004;126:A-138.
5. van Tol EA, Holt L, Li FL, Kong FM, Rippe R, Yamauchi M,
Pucilowska J, Lund PK, Sartor RB. Bacterial cell wall polymers
promote intestinal fibrosis by direct stimulation of myofibro-
blasts. Am J Physiol 1999;277:G245–G255.
6. Sartor RB, Herfarth H, Van Tol EAF. Bacterial cell wall polymer-
induced granulomatous inflammation. Methods 1996;9:233–247.
7. Sartor RB, Cromartie WJ, Powell DW, Schwab JH. Granulomatous
enterocolitis induced in rats by purified bacterial cell wall frag-
ments. Gastroenterology 1985;89:587–595.
8. Greig ER, Rampton DS. Management of Crohn’s Disease. New
York: Martin Dunitz, 2003.
9. Zimmermann EM, Sartor RB, McCall RD, Pardo M, Bender D,
Lund PK. Insulinlike growth factor I and interleukin 1 beta mes-
senger RNA in a rat model of granulomatous enterocolitis and
hepatitis. Gastroenterology 1993;105:399–409.
0. Lawrance IC, Fiocchi C, Chakravarti S. Ulcerative colitis and Crohn’s
disease: distinctive gene expression profiles and novel susceptibil-
ity candidate genes. Hum Mol Genet 2001;10:445–456.
1. Lawrance IC, Maxwell L, Doe W. Inflammation location, but not
type, determines the increase in TGF-beta1 and IGF-1 expression
and collagen deposition in IBD intestine. Inflamm Bowel Dis
2001;7:16–26.
2. Croker BA, Krebs DL, Zhang JG, Wormald S, Willson TA, Stanley EG,
Robb L, Greenhalgh CJ, Forster I, Clausen BE, Nicola NA, Metcalf D,
Hilton DJ, Roberts AW, Alexander WS. SOCS3 negatively regulates
IL-6 signaling in vivo. Nat Immunol 2003;4:540–545.
3. Lovato P, Brender C, Agnholt J, Kelsen J, Kaltoft K, Svejgaard A,
Eriksen KW, Woetmann A, Odum N. Constitutive STAT3 activation
in intestinal T cells from patients with Crohn’s disease. J Biol
Chem 2003;278:16777–16781.
4. Ortiz LA, Lasky J, Gozal E, Ruiz V, Lungarella G, Cavarra E, Brody
AR, Friedman M, Pardo A, Selman M. Tumor necrosis factor
receptor deficiency alters matrix metalloproteinase 13/tissue
inhibitor of metalloproteinase 1 expression in murine silicosis.
Am J Respir Crit Care Med 2001;163:244–252.
5. Guo G, Morrissey J, McCracken R, Tolley T, Liapis H, Klahr S.
Contributions of angiotensin II and tumor necrosis factor-alpha to
the development of renal fibrosis. Am J Physiol 2001;280:F777–
F785.
6. Fox A, Brown RR, Anderle SK, Chetty C, Cromartie WJ, Gooder H,
Schwab JH. Arthropathic properties related to the molecular
weight of peptidoglycan-polysaccharide polymers of streptococ-
cal cell walls. Infect Immun 1982;35:1003–1010.
7. Dahly EM, Miller ME, Lund PK, Ney DM. Postreceptor resistance
to exogenous growth hormone exists in the jejunal mucosa of
parenterally fed rats. J Nutr 2004;134:530–537.
8. Park JH, Vanderhoof JA. Growth hormone did not enhance muco-
sal hyperplasia after small-bowel resection. Scand J Gastroen-
terol 1996;31:349–354.
9. McCall RD, Haskill S, Zimmermann EM, Lund PK, Thompson RC,
Sartor RB. Tissue interleukin 1 and interleukin-1 receptor antag-
onist expression in enterocolitis in resistant and susceptible
rats. Gastroenterology 1994;106:960–972.
0. Ohneda K, Ulshen MH, Fuller CR, D’Ercole AJ, Lund PK. En-
hanced growth of small bowel in transgenic mice expressing
human insulin-like growth factor I. Gastroenterology 1997;
112:444–454.
1. Savendahl L, Underwood LE, Haldeman KM, Ulshen MH, Lund
PK. Fasting prevents experimental murine colitis produced by
dextran sulfate sodium and decreases interleukin-1 beta and
insulin-like growth factor I messenger ribonucleic acid. Endocri-
nology 1997;138:734–740. s2. Rosell DR, Akama KT, Nacher J, McEwen BS. Differential expres-
sion of suppressors of cytokine signaling-1, -2, and -3 in the rat
hippocampus after seizure: implications for neuromodulation by
gp130 cytokines. Neuroscience 2003;122:349–358.
3. Simmons JG, Pucilowska JB, Keku TO, Lund PK. IGF-I and TGF-
beta1 have distinct effects on phenotype and proliferation of
intestinal fibroblasts. Am J Physiol 2002;283:G809–G818.
4. Kaiser GC, Polk DB. Tumor necrosis factor alpha regulates pro-
liferation in a mouse intestinal cell line. Gastroenterology 1997;
112:1231–1240.
5. Adams TE, Hansen JA, Starr R, Nicola NA, Hilton DJ, Billestrup N.
Growth hormone preferentially induces the rapid, transient ex-
pression of SOCS-3, a novel inhibitor of cytokine receptor signal-
ing. J Biol Chem 1998;273:1285–1287.
6. Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ,
Gonda TJ, Alexander WS, Metcalf D, Nicola NA, Hilton DJ. A family
of cytokine-inducible inhibitors of signalling. Nature 1997;387:
917–921.
7. Suzuki A, Hanada T, Mitsuyama K, Yoshida T, Kamizono S,
Hoshino T, Kubo M, Yamashita A, Okabe M, Takeda K, Akira S,
Matsumoto S, Toyonaga A, Sata M, Yoshimura A. CIS3/SOCS3/
SSI3 plays a negative regulatory role in STAT3 activation and
intestinal inflammation. J Exp Med 2001;193:471–481.
8. Miller ME, Michaylira CZ, Simmons JG, Ney DM, Dahly EM, Heath
JK, Lund PK. Suppressor of cytokine signaling-2: a growth hor-
mone-inducible inhibitor of intestinal epithelial cell proliferation.
Gastroenterology 2004;127:570–581.
9. Fruchtman S, Simmons JG, Michaylira CZ, Miller ME, Greenhalgh
CJ, Ney DM, Lund PK. Suppressor of cytokine signaling-2
(SOCS-2) modulates the fibrogenic actions of GH and IGF-I in
intestinal mesenchymal cells. Am J Physiol 2005 (in press).
0. Fukushima R, Saito H, Inoue T, Fukatsu K, Inaba T, Han I,
Furukawa S, Lin MT, Muto T. Prophylactic treatment with growth
hormone and insulin-like growth factor I improve systemic bacte-
rial clearance and survival in a murine model of burn-induced
gut-derived sepsis. Burns 1999;25:425–430.
1. Shouda T, Yoshida T, Hanada T, Wakioka T, Oishi M, Miyoshi K,
Komiya S, Kosai K, Hanakawa Y, Hashimoto K, Nagata K, Yo-
shimura A. Induction of the cytokine signal regulator SOCS3/
CIS3 as a therapeutic strategy for treating inflammatory arthritis.
J Clin Invest 2001;108:1781–1788.
2. Hong-Brown LQ, Brown CR, Cooney RN, Frost RA, Lang CH.
Sepsis-induced muscle growth hormone resistance occurs inde-
pendently of STAT5 phosphorylation. Am J Physiol 2003;285:
E63–E72.
3. Lobie PE, Breipohl W, Waters MJ. Growth hormone receptor
expression in the rat gastrointestinal tract. Endocrinology 1990;
126:299–306.
4. Greenhalgh CJ, Miller ME, Hilton DJ, Lund PK. Suppressors of
cytokine signaling: relevance to gastrointestinal function and
disease. Gastroenterology 2002;123:2064–2081.
Received October 16, 2004. Accepted March 30, 2005.
Address requests for reprints to: P. Kay Lund/Arianne Theiss,
B#7545, Department of Cell and Molecular Physiology, University of
orth Carolina at Chapel Hill, Chapel Hill, North Carolina 27599-7545.
-mail: empk@med.unc.edu; fax: (919) 966-6927.
Supported by National Institute of Diabetes and Digestive and Kid-
ey Diseases grant R01 DK-47769 (to P.K.L., R.B.S.). This study was
acilitated by the Molecular Histopathology Core of the Center for
astrointestinal Biology and Disease (National Institutes of Health
30-DK-34987).
The authors thank Kirk McNaughton for his expert assistance with
istology, which was instrumental for both fibrosis and inflammation
coring.
